By Fineline Cube 
China-based biotech Zai Lab Ltd (NASDAQ: ZLAB, HKG: 9688) presented the latest results from the Phase Ia/Ib study (NCT06179069) of its Delta-like ligand (DLL3) antibody-drug conjugate (ADC) zocilurtatug pelitecan (ZL-1310) at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting. The study evaluated the drug in patients with extensive-stage small cell lung cancer (ES-SCLC).
Clinical Trial Results
Across all dose levels in the second-line (2L) treatment setting (n=33), the unconfirmed objective response rate (uORR) was 67%, and the disease control rate (DCR) reached 97%. The most promising combination of response and tolerability was observed in the 1.6 mg/kg arm (n=14), where the uORR was 79% and the DCR was 100%. Among the 22 response-evaluable patients with baseline brain metastases, a 68% ORR was observed. In patients without prior cranial irradiation, the ORR was 86%.
Safety Profile
ZL-1310 continues to demonstrate a well-tolerated safety profile, particularly at doses less than 2.0 mg/kg, highlighting its potential as a effective treatment option for ES-SCLC patients.-Fineline Info & Tech